Report cover image

Wearable Breast Pump Market

Publisher Grand View Research
Published Jan 27, 2026
Length 175 Pages
SKU # GV20873275

Description

Wearable Breast Pump Market Summary

The global wearable breast pump market size was estimated at USD 642.0 million in 2025 and is projected to reach USD 1,193.9 million by 2033, growing at a CAGR of 8.1% from 2026 to 2033. This growth is attributed to the increasing participation of women in the workforce, rising awareness about the benefits of breastfeeding, growing preference for hands-free and discreet pumping solutions, and continuous technological advancements in wearable pump design, including quieter motors, improved suction efficiency, and smart connectivity features.

The growing number of working women is driving the wearable breast pump market, as employed mothers seek convenient, hands-free solutions that allow them to express milk while balancing professional and personal responsibilities. Wearable breast pumps offer mobility, discreet use, and time-saving benefits, enabling women to maintain breastfeeding routines without interrupting work. Increasing awareness of the health benefits of breastfeeding, supportive workplace policies, and rising participation of women in the workforce are collectively fueling demand for advanced, portable, and user-friendly breast pump solutions.

Global Wearable Breast Pump Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global wearable breast pump market report based on component, technology, distribution channel, and region:
  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Wearable Pumps
  • Accessories
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Manual Wearable Breast Pump
  • Battery Operated Wearable Breast Pump
  • Smart Wearable Breast Pump
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Online
  • Offline
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

175 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Application
1.2.3. Product
1.2.4. Route of Administration
1.2.5. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Generic Pharmaceuticals Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Generic Pharmaceuticals Market: Type Business Analysis
4.1. Type Market Share, 2025 & 2033
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Simple Generics
4.4.1. Simple Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Specialty Generics
4.5.1. Specialty Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Biosimilars
4.6.1. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Generic Pharmaceuticals Market: Application Business Analysis
5.1. Application Market Share, 2025 & 2033
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Central Nervous System Disorders
5.4.1. Central Nervous System Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Respiratory Diseases
5.5.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Hormones and Related Diseases
5.6.1. Hormones and Related Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Gastrointestinal Diseases
5.7.1. Gastrointestinal Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Cardiovascular Diseases
5.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Infectious Diseases
5.9.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. Cancer
5.10.1. Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Diabetes
5.11.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12. Others
5.12.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Generic Pharmaceuticals Market: Product Business Analysis
6.1. Product Market Share, 2025 & 2033
6.2. Product Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
6.4. Small Molecule
6.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Large Molecule
6.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Generic Pharmaceuticals Market: Route of Administration Business Analysis
7.1. Route of Administration Market Share, 2025 & 2033
7.2. Route of Administration Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
7.4. Oral
7.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Injectable
7.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Inhalable
7.6.1. Inhalable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Others
7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Generic Pharmaceuticals Market: Distribution Channel Business Analysis
8.1. Distribution Channel Market Share, 2025 & 2033
8.2. Distribution Channel Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
8.4. Online Pharmacies
8.4.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Retail Pharmacies
8.5.1. Retail Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Hospital Pharmacies
8.6.1. Hospital Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Generic Pharmaceuticals Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2025 & 2033
9.2. Regional Market Dashboard
9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
9.4. North America
9.4.1. North America Generic Pharmaceuticals Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
9.4.2. U.S.
9.4.2.1. Key Country Dynamics
9.4.2.2. Type Disease Prevalence
9.4.2.3. Regulatory Framework
9.4.2.4. Reimbursement Framework
9.4.2.5. U.S. Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.3. Canada
9.4.3.1. Key Country Dynamics
9.4.3.2. Type Disease Prevalence
9.4.3.3. Regulatory Framework
9.4.3.4. Reimbursement Framework
9.4.3.5. Canada Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.4. Mexico
9.4.4.1. Key Country Dynamics
9.4.4.2. Type Disease Prevalence
9.4.4.3. Regulatory Framework
9.4.4.4. Reimbursement Framework
9.4.4.5. Mexico Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Europe
9.5.1. Europe Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.2. UK
9.5.2.1. Key Country Dynamics
9.5.2.2. Type Disease Prevalence
9.5.2.3. Regulatory Framework
9.5.2.4. Reimbursement Framework
9.5.2.5. UK Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.3. Germany
9.5.3.1. Key Country Dynamics
9.5.3.2. Type Disease Prevalence
9.5.3.3. Regulatory Framework
9.5.3.4. Reimbursement Framework
9.5.3.5. Germany Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.4. France
9.5.4.1. Key Country Dynamics
9.5.4.2. Type Disease Prevalence
9.5.4.3. Regulatory Framework
9.5.4.4. Reimbursement Framework
9.5.4.5. France Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.5. Italy
9.5.5.1. Key Country Dynamics
9.5.5.2. Type Disease Prevalence
9.5.5.3. Regulatory Framework
9.5.5.4. Reimbursement Framework
9.5.5.5. Italy Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.6. Spain
9.5.6.1. Key Country Dynamics
9.5.6.2. Type Disease Prevalence
9.5.6.3. Regulatory Framework
9.5.6.4. Reimbursement Framework
9.5.6.5. Spain Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.7. Denmark
9.5.7.1. Key Country Dynamics
9.5.7.2. Type Disease Prevalence
9.5.7.3. Regulatory Framework
9.5.7.4. Reimbursement Framework
9.5.7.5. Denmark Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.8. Sweden
9.5.8.1. Key Country Dynamics
9.5.8.2. Type Disease Prevalence
9.5.8.3. Regulatory Framework
9.5.8.4. Reimbursement Framework
9.5.8.5. Sweden Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.9. Norway
9.5.9.1. Key Country Dynamics
9.5.9.2. Type Disease Prevalence
9.5.9.3. Regulatory Framework
9.5.9.4. Reimbursement Framework
9.5.9.5. Norway Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Asia Pacific
9.6.1. Asia Pacific Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.2. Japan
9.6.2.1. Key Country Dynamics
9.6.2.2. Type Disease Prevalence
9.6.2.3. Regulatory Framework
9.6.2.4. Reimbursement Framework
9.6.2.5. Japan Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.3. China
9.6.3.1. Key Country Dynamics
9.6.3.2. Type Disease Prevalence
9.6.3.3. Regulatory Framework
9.6.3.4. Reimbursement Framework
9.6.3.5. China Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.4. India
9.6.4.1. Key Country Dynamics
9.6.4.2. Type Disease Prevalence
9.6.4.3. Regulatory Framework
9.6.4.4. Reimbursement Framework
9.6.4.5. India Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.5. Australia
9.6.5.1. Key Country Dynamics
9.6.5.2. Type Disease Prevalence
9.6.5.3. Regulatory Framework
9.6.5.4. Reimbursement Framework
9.6.5.5. Australia Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.6. South Korea
9.6.6.1. Key Country Dynamics
9.6.6.2. Type Disease Prevalence
9.6.6.3. Regulatory Framework
9.6.6.4. Reimbursement Framework
9.6.6.5. South Korea Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.7. Thailand
9.6.7.1. Key Country Dynamics
9.6.7.2. Type Disease Prevalence
9.6.7.3. Regulatory Framework
9.6.7.4. Reimbursement Framework
9.6.7.5. Thailand Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7. Latin America
9.7.1. Latin America Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7.2. Brazil
9.7.2.1. Key Country Dynamics
9.7.2.2. Type Disease Prevalence
9.7.2.3. Regulatory Framework
9.7.2.4. Reimbursement Framework
9.7.2.5. Brazil Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7.3. Argentina
9.7.3.1. Key Country Dynamics
9.7.3.2. Type Disease Prevalence
9.7.3.3. Regulatory Framework
9.7.3.4. Reimbursement Framework
9.7.3.5. Argentina Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8. Middle East and Africa
9.8.1. Middle East and Africa Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8.2. South Africa
9.8.2.1. Key Country Dynamics
9.8.2.2. Type Disease Prevalence
9.8.2.3. Regulatory Framework
9.8.2.4. Reimbursement Framework
9.8.2.5. South Africa Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8.3. Saudi Arabia
9.8.3.1. Key Country Dynamics
9.8.3.2. Type Disease Prevalence
9.8.3.3. Regulatory Framework
9.8.3.4. Reimbursement Framework
9.8.3.5. Saudi Arabia Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8.4. UAE
9.8.4.1. Key Country Dynamics
9.8.4.2. Type Disease Prevalence
9.8.4.3. Regulatory Framework
9.8.4.4. Reimbursement Framework
9.8.4.5. UAE Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8.5. Kuwait
9.8.5.1. Key Country Dynamics
9.8.5.2. Type Disease Prevalence
9.8.5.3. Regulatory Framework
9.8.5.4. Reimbursement Framework
9.8.5.5. Kuwait Generic Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Participant Overview
10.2. Company Market Position Analysis
10.3. Company Categorization
10.4. Strategy Mapping
10.5. Company Profiles/Listing
10.5.1. Teva Pharmaceutical Industries
10.5.1.1. Overview
10.5.1.2. Financial Performance
10.5.1.3. Type Benchmarking
10.5.1.4. Strategic Initiatives
10.5.2. Sandoz
10.5.2.1. Overview
10.5.2.2. Financial Performance
10.5.2.3. Type Benchmarking
10.5.2.4. Strategic Initiatives
10.5.3. Sun Pharmaceutical Industries
10.5.3.1. Overview
10.5.3.2. Financial Performance
10.5.3.3. Type Benchmarking
10.5.3.4. Strategic Initiatives
10.5.4. Viatris
10.5.4.1. Overview
10.5.4.2. Financial Performance
10.5.4.3. Type Benchmarking
10.5.4.4. Strategic Initiatives
10.5.5. Dr. Reddy’s Laboratories
10.5.5.1. Overview
10.5.5.2. Financial Performance
10.5.5.3. Type Benchmarking
10.5.5.4. Strategic Initiatives
10.5.6. Cipla
10.5.6.1. Overview
10.5.6.2. Financial Performance
10.5.6.3. Type Benchmarking
10.5.6.4. Strategic Initiatives
10.5.7. Aurobindo Pharma
10.5.7.1. Overview
10.5.7.2. Financial Performance
10.5.7.3. Type Benchmarking
10.5.7.4. Strategic Initiatives
10.5.8. Lupin
10.5.8.1. Overview
10.5.8.2. Financial Performance
10.5.8.3. Type Benchmarking
10.5.8.4. Strategic Initiatives
10.5.9. Glenmark Pharmaceuticals
10.5.9.1. Overview
10.5.9.2. Financial Performance
10.5.9.3. Type Benchmarking
10.5.9.4. Strategic Initiatives
10.5.10. Torrent Pharmaceuticals
10.5.10.1. Overview
10.5.10.2. Financial Performance
10.5.10.3. Type Benchmarking
10.5.10.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us